CollPlant Biotechnologies Past Earnings Performance
Past criteria checks 0/6
CollPlant Biotechnologies's earnings have been declining at an average annual rate of -17.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 5.9% per year.
Key information
-17.3%
Earnings growth rate
3.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -5.9% |
| Return on equity | -103.0% |
| Net Margin | -2,680.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Aug 20
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Feb 03Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?
Nov 02CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business
Sep 06Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Jul 14Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Mar 02Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth
Nov 10CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M
Aug 25We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Jul 22CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 22CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
Aug 05Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation
Jul 29The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business
Jun 09Revenue & Expenses Breakdown
How CollPlant Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -17 | 6 | 11 |
| 30 Jun 24 | 1 | -17 | 6 | 11 |
| 31 Mar 24 | 11 | -7 | 6 | 11 |
| 31 Dec 23 | 11 | -7 | 6 | 10 |
| 30 Sep 23 | 11 | -7 | 7 | 9 |
| 30 Jun 23 | 11 | -7 | 6 | 10 |
| 31 Mar 23 | 1 | -17 | 7 | 9 |
| 31 Dec 22 | 0 | -17 | 7 | 10 |
| 30 Sep 22 | 1 | -16 | 6 | 9 |
| 30 Jun 22 | 1 | -15 | 6 | 9 |
| 31 Mar 22 | 1 | -14 | 6 | 8 |
| 31 Dec 21 | 16 | 0 | 6 | 8 |
| 30 Sep 21 | 16 | 1 | 6 | 7 |
| 30 Jun 21 | 20 | 5 | 6 | 6 |
| 31 Mar 21 | 20 | 6 | 6 | 5 |
| 31 Dec 20 | 6 | -6 | 5 | 4 |
| 30 Sep 20 | 6 | -7 | 4 | 4 |
| 30 Jun 20 | 3 | -11 | 4 | 4 |
| 31 Mar 20 | 2 | -11 | 4 | 4 |
| 31 Dec 19 | 2 | -11 | 4 | 4 |
| 30 Sep 19 | 6 | -6 | 3 | 5 |
| 30 Jun 19 | 6 | -6 | 4 | 4 |
| 31 Mar 19 | 5 | -4 | 3 | 5 |
| 31 Dec 18 | 5 | -6 | 4 | 4 |
| 30 Sep 18 | 1 | -6 | 4 | 4 |
| 30 Jun 18 | 1 | -6 | 3 | 3 |
| 31 Mar 18 | 1 | -7 | 3 | 4 |
| 31 Dec 17 | 0 | -6 | 2 | 4 |
| 30 Sep 17 | 0 | -6 | 3 | 4 |
| 30 Jun 17 | 0 | -7 | 3 | 4 |
| 31 Mar 17 | 0 | -7 | 3 | 4 |
| 31 Dec 16 | 0 | -7 | 3 | 4 |
| 30 Sep 16 | 0 | -7 | 2 | 5 |
| 30 Jun 16 | 0 | -7 | 2 | 4 |
| 31 Mar 16 | 0 | -6 | 2 | 4 |
| 31 Dec 15 | 0 | -5 | 2 | 3 |
| 30 Sep 15 | 0 | -4 | 1 | 3 |
| 30 Jun 15 | 0 | -4 | 1 | 3 |
| 31 Mar 15 | 0 | -3 | 1 | 2 |
| 31 Dec 14 | 0 | -3 | 1 | 2 |
| 30 Sep 14 | 0 | -4 | 1 | 3 |
| 30 Jun 14 | 0 | -4 | 1 | 3 |
Quality Earnings: CLGN is currently unprofitable.
Growing Profit Margin: CLGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLGN is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare CLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: CLGN has a negative Return on Equity (-102.97%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 09:22 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Linda Pomeroy | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |